<p><strong>Overview</strong>: The <span class="key-term" data-definition="World Health Organization — UN agency that coordinates international health work, monitors disease outbreaks, and provides technical guidance (GS1: Health, GS3: International Institutions)">WHO</span> is assessing candidate vaccines and treatments to curb a rapidly spreading <span class="key-term" data-definition="Ebola — A viral haemorrhagic fever with high fatality, posing major public‑health challenges (GS1: Health)">Ebola</span> outbreak in the Democratic Republic of Congo (DRC). The surge has killed <strong>131 people</strong> and infected over <strong>500</strong>, prompting an international health emergency declaration.</p>
<h3>Key Developments</h3>
<ul>
<li>WHO representative <span class="key-term" data-definition="Anne Ancia — WHO’s senior official for the DRC, responsible for field coordination (GS1: Health)">Anne Ancia</span> said the agency is reviewing all candidate vaccines and therapeutics.</li>
<li><span class="key-term" data-definition="Tedros Adhanom Ghebreyesus — Director‑General of WHO, leading global health policy (GS1: Health)">Tedros Adhanom Ghebreyesus</span> expressed deep concern and will convene an emergency meeting on the crisis.</li>
<li>There is no approved vaccine for the <span class="key-term" data-definition="Bundibugyo strain — A variant of Ebola virus not covered by existing vaccines, increasing response complexity (GS1: Health)">Bundibugyo strain</span> causing the current outbreak.</li>
<li>Existing vaccines target the <span class="key-term" data-definition="Zaire strain — The original Ebola virus identified in 1976; current licensed vaccine Ervebo is for this strain (GS1: Health)">Zaire strain</span>, and pre‑qualified vaccines cannot be used now.</li>
<li>The vaccine candidate <span class="key-term" data-definition="Ervebo — WHO‑approved vaccine for Zaire Ebola, requiring two months for deployment (GS1: Health)">Ervebo</span> is under review and may become available after about two months.</li>
</ul>
<h3>Important Facts</h3>
<ul>
<li>This is the <strong>17th</strong> Ebola outbreak in the DRC.</li>
<li>The deadliest DRC outbreak (2018‑2020) claimed <strong>2,300 lives</strong>.</li>
<li>WHO has deployed more than <strong>40 experts</strong> and sent <strong>12 tonnes</strong> of supplies, including <span class="key-term" data-definition="Personal Protective Equipment — Gear such as masks, gloves, and gowns that protect health workers from infection (GS3: Health Infrastructure)">PPE</span>, from Kinshasa and Nairobi.</li>
<li>Collaboration with <span class="key-term" data-definition="Doctors Without Borders — International medical humanitarian NGO that provides emergency care in conflict zones (GS2: Polity, GS4: Ethics)">Doctors Without Borders</span> is underway to set up treatment centres.</li>
<li>The WHO technical advisory group will meet to prioritise vaccine candidates.</li>
</ul>
<h3>UPSC Relevance</h3>
<p>Understanding the WHO’s role highlights the importance of <strong>global health governance</strong> (GS1). The distinction between virus strains (Bundibugyo vs. Zaire) illustrates challenges in <strong>vaccine development and deployment</strong>, a recurring theme in health‑policy questions. The coordination with NGOs like Doctors Without Borders underscores the need for <strong>public‑private partnerships</strong> in disaster response, relevant to GS2 (Polity) and GS4 (Ethics). The emergency meeting convened by the Director‑General reflects decision‑making mechanisms in international organisations, a typical UPSC case study.</p>
<h3>Way Forward</h3>
<p>WHO will finalise vaccine prioritisation, aim to secure <span class="key-term" data-definition="Ervebo — WHO‑approved vaccine for Zaire Ebola, requiring two months for deployment (GS1: Health)">Ervebo</span> or other candidates, and expand laboratory capacity. Strengthening <span class="key-term" data-definition="Personal Protective Equipment — Gear such as masks, gloves, and gowns that protect health workers from infection (GS3: Health Infrastructure)">PPE</span> supplies and field teams remains critical. Continuous monitoring and rapid response are essential to prevent the outbreak from extending beyond the projected two‑month window.</p>